BIOCONBiocon Limited
Convert to ideaPharmaceuticals & Biotechnology · Biotechnology
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 1.0 this quarter.
Momentum from moving averages, Supertrend and RSI.
5 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
5 found · risk watch
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹4389 Cr | ₹57 Cr | 6.09% | 1.29% | ₹0.25 | 1.2x |
| Q1 FY2027 | ₹4336 Cr | ₹137 Cr | 6.91% | 3.15% | ₹0.87 | 1.6x |
| Q4 FY2026 | ₹4517 Cr | ₹199 Cr | 11.22% | 4.40% | ₹0.79 | 2.1x |
| Q3 FY2026 | ₹4173 Cr | ₹-52 Cr | 7.63% | -1.24% | ₹1.08 | 0.7x |
| Q2 FY2026 | ₹4296 Cr | ₹133 Cr | 8.44% | 3.09% | ₹0.66 | 1.6x |
| Q1 FY2026 | ₹3942 Cr | ₹89 Cr | 7.46% | 2.26% | ₹0.26 | 1.4x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Biotechnology
Compare with peers →Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.